Investors on the lookout for consistency should turn to Alcon , JPMorgan said. The bank upgraded the eye care stock to obese from neutral Thursday. It also raised its price goal to $89.30 per share from $79.80. JPMorgan’s forecast implies roughly 11% upside from Wednesday’s $80.24 close. JPMorgan’s call comes after Alcon, which makes Opti-Free contact lens solution, reported better-than-expected second-quarter results Wednesday. The corporate also raised its full-year earnings guidance. Nonetheless, the stock only rose marginally on the back of that report. But analyst David Adlington says that despite the fact that shares didn’t meaningfully pop after the earnings beat, the corporate has several growth drivers elsewhere, including in its implantable segment and overall higher equipment volume. “We acknowledge this reporting season has seen quite a lot of share prices within the sector struggle even with ‘beats & raises’ — but there had been quite a lot of anticipation in-built elsewhere,” Adlington said. “The positive earnings’ momentum looks set to proceed.” Alcon stock has added greater than 17% in 2023. ALC YTD mountain Alcon yr thus far. — CNBC’s Michael Bloom contributed to this report.